Article
Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals.
Cancer letters - 8 Jul 2008
Zhu Jian-quan, Zhong Wen-zhao, Zhang Guo-chun, Li Rong, Zhang Xu-chao, Guo Ai-lin, Zhang Yi-fang, An She-juan, Mok Tony S, Wu Yi-long
Abstract excerpt
Somatic mutations in the epidermal growth factor receptor (EGFR) kinase domain are associated with sensitivity to tyrosine kinase inhibitors (TKIs) in patients with non-small cell lung cancer (NSCLC). Our clinical data showed NSCLC patients with exon 19 deletions survived longer following gefitinib treatment than those with exon 21 point mutations. We aimed to investigate whether these two mutations produced...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.